Pro00077024 Phase 2 Study

Recurrent glioblastoma is a devastating disease with few viable treatments. Istari Oncology is sponsoring a clinical trial open to recruitment that investigates a novel treatment option at multiple centers throughout the U.S., and we encourage you to learn more.

Our Phase 2 clinical trial of PVSRIPO, a genetically modified anti-tumor virus, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma (also known as glioblastoma multiforme, or GBM) is actively recruiting. The objective of this study is to investigate the safety and efficacy (anti-tumor response and survival) of PVSRIPO in patients experiencing their first or second GBM recurrence, after receiving standard of care therapies.

If you would like to learn more about PVSRIPO please visit the Preston Robert Tisch Brain Tumor Center (founding center)

Phase 2 Clinical Trial

Questions? Contact us.